Global Theranostics Market Size by Impeller Therapeutic, Technology, End user and Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032
Overview
Global Theranostics Market size was valued at USD 2.8 Bn in 2025 and is expected to reach USD 7.81 Bn by 2032, at a CAGR of 15.78% during a forecast period.
Theranostics Market Overview:
The term theranostics refers to the use of one radioactive medicine to identify (diagnose) and another radioactive drug to give therapy to treat the primary tumour as well as any metastatic tumours. One sort of radioactive isotope, Gallium, is used in theranostics to discover or diagnose malignant targets known as tumour receptors. It then treats them with a different type of radioactive isotope called Lutetium.
To know about the Research Methodology :- Request Free Sample Report
Theranostics Market Dynamics:
As cancer occurrences continue to rise and side-effects of procedures like chemotherapy continue to be a challenge for clinicians, the theranostics market is expected to grow rapidly. Furthermore, because recovery is often protracted and requires time away from patients' daily routines, post-cancer care promises lucrative growth. The rise of tumours such as brain, kidney, liver, and breast, among others, presents a plethora of prospects for theranostics players. Growing research and development, as well as hopeful FDA approvals in the pipeline, are expected to continue to drive theranostics market growth.
The high costs of therapy, as well as the fact that it is still experimental, are expected to be major restraints to the growth of the theranostics market. Furthermore, healthcare costs and a lack of information regarding post-cancer treatments are expected to be obstacles in places such as North America. Rising awareness, on the other hand, is expected to open up new chances for theranostics players.
Theranostics market growth is expected to be driven by ongoing developments in cancer treatments to overcome the negative effects of current treatment approaches.
The global theranostics market is being driven by the increased prevalence of chronic diseases, the demand for innovative chemotherapeutic therapies, and the need to improve disease detection. In 2017, Illumina, Inc. stated that the US Food and Drug Administration (FDA) had authorised an extended RAS panel for identifying patients who are candidates for Vectibix treatment for metastatic colorectal cancer (panitumumab). Market growth is expected to be driven by shorter medical trial times and increased collaboration between medication and diagnostics companies. In addition, the growing usage of potentially useful and clinically applicable nanomaterial’s in biological imaging and therapy is expected to boost market growth. Biocartis Group NV and Amgen Inc. teamed together in 2018 to develop a companion diagnostic test for Amgen's Veectibix medication.
Theranostics Market Segment Analysis:
By product type, the Drugs segment, particularly radiopharmaceuticals, held the maximum market share in 2025. Their dominance is attributed to their dual diagnostic and therapeutic capabilities, enabling precise targeting of diseased tissues while minimizing systemic toxicity. Radiopharmaceuticals are widely utilized in PET and SPECT imaging and targeted radionuclide therapy, especially in oncology applications such as prostate and neuroendocrine cancers. Strong R&D investments, increasing regulatory approvals, and expanding clinical adoption in hospitals and specialty centers significantly contributed to the segment’s leadership position in 2025.
By technology, the Nanoparticle-Based Theranostics segment is projected to grow at the fastest CAGR during 2026–2032. The segment’s rapid expansion is driven by its strong potential in targeted drug delivery, improved bioavailability, and enhanced tumor penetration. Nanoparticles such as liposomes, polymeric nanoparticles, and gold nanoparticles enable controlled drug release and improved stability of therapeutic agents. Their ability to cross complex biological barriers, including the blood-brain barrier, further expands applications in neurological and metastatic cancers. Increasing research in nanomedicine and precision oncology is accelerating commercial adoption globally.
Theranostics Market Regional Insights:
In 2025, North America accounted for the largest share of the global theranostics market. The region’s dominance is supported by advanced healthcare infrastructure, strong nuclear medicine capabilities, and high adoption of precision oncology solutions. Rising incidence of prostate and neuroendocrine cancers, favorable reimbursement frameworks, and active participation of leading companies such as GE HealthCare and Siemens Healthineers AG further strengthened regional growth. Additionally, significant clinical research activities and regulatory support accelerated commercialization of innovative theranostic agents across the U.S. and Canada.
During the forecast period, Asia Pacific is anticipated to register the fastest growth in the theranostics market. The region’s expansion is supported by rising cancer prevalence, improving healthcare infrastructure, and growing investments in nuclear medicine capabilities. Countries such as China, Japan, and India are increasingly adopting advanced molecular imaging technologies and radiopharmaceutical therapies. Government initiatives promoting domestic isotope production and personalized medicine are further strengthening market penetration. Additionally, collaborations with global players such as Curium Pharma are accelerating clinical development and commercialization across the region.
The objective of the report is to present a comprehensive analysis of the Global Theranostics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The reports also help in understanding the Global Theranostics Market dynamic, structure by analyzing the market segments and project the Global Theranostics Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Theranostics Market make the report investor’s guide.
Theranostics Market Scope: Inquire before buying
| Global Theranostics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 2.8 USD Bn |
| Forecast Period 2026-2032 CAGR: | 15.78% | Market Size in 2032: | 7.81 USD Bn |
| Segments Covered: | By Product Type | Drugs Imaging Agents Devices & Instruments |
|
| By Technology | Molecular Imaging Nanoparticle-Based Theranostics Radiopharmaceuticals Radiopharmaceuticals |
||
| By Application | Oncology Cardiovascular Diseases Neurological Disorders Infectious Diseases Autoimmune Disorders Others |
||
| By End User | Hospitals & Clinics Diagnostic Imaging Centers Academic & Research Institutes Specialty Care Centers Others |
||
Theranostics Market, by Region
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
Key Players/Competitors Profile, Covered in Global Theranostics Market Report, From A Strategic Perspective.
1. F. Hoffmann-La Roche Ltd
2. Thermo Fisher Scientific Inc.
3. GE HealthCare
4. Siemens Healthineers AG
5. Agilent Technologies
6. QIAGEN N.V.
7. Foundation Medicine, Inc.
8. Leica Biosystems Nussloch GmbH
9. Pfizer Inc.
10. Beckman Coulter, Inc.
11. Focus Diagnostics
12. Illumina, Inc.
13. Abbott Laboratories
14. Myriad Genetics, Inc.
15. AmeriPath, Inc.
16. Bracco Imaging S.p.A.
17. Bayer AG
18. Novartis AG
19. Lantheus Holdings, Inc.
20. Telix Pharmaceuticals Limited
21. Curium Pharma
22. Jubilant Radiopharma
23. Advanced Accelerator Applications S.A.
24. Cardinal Health, Inc.
25. Philips Healthcare